Repligen Co. (NASDAQ:RGEN) Shares Sold by Amalgamated Bank

Amalgamated Bank lowered its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 16.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,819 shares of the biotechnology company's stock after selling 5,536 shares during the quarter. Amalgamated Bank owned approximately 0.05% of Repligen worth $5,300,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Benjamin F. Edwards & Company Inc. increased its position in Repligen by 152.1% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company's stock valued at $43,000 after acquiring an additional 146 shares during the period. Signaturefd LLC raised its stake in shares of Repligen by 44.1% during the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 86 shares in the last quarter. Principal Securities Inc. bought a new stake in shares of Repligen during the fourth quarter valued at about $48,000. Milestone Investment Advisors LLC acquired a new stake in Repligen in the third quarter worth about $61,000. Finally, CWM LLC grew its position in Repligen by 19.9% in the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company's stock valued at $66,000 after buying an additional 60 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

RGEN has been the subject of several recent analyst reports. Stifel Nicolaus increased their price objective on shares of Repligen from $165.00 to $207.00 and gave the company a "buy" rating in a report on Thursday, February 22nd. KeyCorp lifted their price target on Repligen from $210.00 to $220.00 and gave the company an "overweight" rating in a research report on Thursday, February 15th. Finally, JPMorgan Chase & Co. cut their price objective on Repligen from $230.00 to $200.00 and set an "overweight" rating for the company in a report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Repligen has an average rating of "Moderate Buy" and an average target price of $197.75.

Repligen Trading Down 0.1 %

NASDAQ RGEN traded down $0.16 on Monday, hitting $171.78. 319,879 shares of the company were exchanged, compared to its average volume of 528,083. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13. The company's 50 day moving average price is $175.20 and its 200-day moving average price is $177.14. The firm has a market capitalization of $9.60 billion, a P/E ratio of 687.15, a price-to-earnings-growth ratio of 5.75 and a beta of 1.03. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The firm had revenue of $151.31 million during the quarter, compared to analysts' expectations of $150.06 million. During the same quarter last year, the company posted $0.64 EPS. The firm's revenue was down 17.1% compared to the same quarter last year. Analysts predict that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In related news, COO James Bylund sold 4,373 shares of the firm's stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the sale, the chief operating officer now directly owns 14,135 shares in the company, valued at $2,799,860.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Repligen news, COO James Bylund sold 4,373 shares of the company's stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the transaction, the chief operating officer now directly owns 14,135 shares of the company's stock, valued at approximately $2,799,860.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the sale, the chief executive officer now owns 185,249 shares of the company's stock, valued at $36,575,562.56. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock valued at $5,039,532 in the last 90 days. 1.20% of the stock is currently owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.